MRNA vaccines: this is just the beginning

These days we celebrate World Immunization Week by providing an opportunity to reflect on the importance of vaccines and immunization. Vaccines rank second after access to drinking water in terms of public health impact. Last year, in particular, highlighted their importance and gave us hope that vaccines can help fight the SARS-CoV-2 pandemic and other deadly diseases.

Over the past year, we have realized the tremendous potential for breakthrough that mRNA vaccines can bring. We humbly offered our mRNA vaccine to help fight COVID-19.

At Moderna, we are committed to continuing to leverage the power of our platform to accelerate the development of our mRNA vaccine portfolio. This gives us hope that we can help overcome this pandemic and do much more in the future.

Continuous search

Our team of scientists has been researching and developing mRNA since 2010. Today, we employ 1,300 people who are rushing to stay at the forefront as we live in a busy time.

We believe we have a unique opportunity to develop new vaccines against pathogens affecting populations around the world, at a pace that is radically different from the industry’s so far.

In addition to COVID-19, we are developing vaccines against other viruses that harm humans and which need to be addressed. We plan to begin a phase 3 clinical trial of our cytomegalovirus (CMV) vaccine candidate in 2021. This is especially important as CMV is one of the leading infectious causes of birth defects worldwide. We are also working on an approach to using mRNA for an influenza vaccine and plan to begin Phase 1 research on our candidate vaccine later this year.

We also recognize that we cannot maximize the potential of mRNA without ensuring that access to these vaccines and drugs is open to all communities. This is why we slowed down the COVE Phase 3 study of our COVID-19 vaccine in the United States to make sure our sample is representative of the communities most at risk and the diversity of our society.

Our work doesn’t end there, as we are applying what we have learned from our COVID-19 research into our upcoming Phase 3 CMV vaccine study. We recently shared our demographic recruitment goals for this study and are committed to transparency and achievement. goals.

Other diseases

Our work doesn’t stop with vaccines. We harness the full power of mRNA to treat rare diseases, cardiovascular disease, autoimmune diseases, and more. We are committed to applying our mRNA vaccine platform to a multitude of diseases, and we are confident that Moderna’s breakthroughs can materialize.

Our mission is to deliver on the promise of mRNA science and create the next generation of transforming drugs for patients. We think this is just the beginning.

Stefan Bansel, Chairman and CEO of Moderna

Stephen Hoge, MD, President, Moderna

Jacqueline Miller, MD, Vice President and Head of Infectious Diseases, Moderna

Back to top button